A Phase I Study of ABT-888 in Combination With Oxaliplatin and Capecitabine in Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 12 Feb 2016
At a glance
- Drugs Veliparib (Primary) ; Capecitabine; Oxaliplatin
- Indications Solid tumours
- Focus Adverse reactions
- 07 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 17 Jul 2013 Planned end date changed from 1 Jul 2013 to 1 Jul 2014 as reported by ClinicalTrials.gov.
- 26 Mar 2013 Planned number of patients changed from 48 to 36 as reported by ClinicalTrials.gov.